Background: The rapid failure of initial therapy with combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that exclude zidovudine has not been fully explained by standard virus population analyses of HIV type-1 (HIV-1) drug resistance. We therefore investigated HIV-1 genotype and phenotype at the single genome level in samples from patients on a failing regimen of tenofovir (TNV), didanosine (ddI) and lamivudine (3TC). Methods: Single genome sequencing was performed on 9 failure samples containing both K65R and M184V mutations by standard genotype, either as wild-type/mutant mixtures (6/9) or as mutant only (3/9). Recombinant clones with different combinations of observed mutations were generated and tested for NRTI susceptibility. Results: Of the 204 single genome sequences analysed, 50% were K65R/M184V double mutants, 38% were M184V single mutants, 10% were M184I single mutants and only 1% (2 sequences) were K65R single mutants. Phenotypic testing of recombinant clones showed a significant increase in resistance for double mutants: mean fold resistance to abacavir, ddI and TNV was 6.5, 4.3 and 1.6 for K65R/M184V double mutants versus 2.5, 1.9 and 0.6 for M184V single mutants, respectively (P<0.001). Conclusions: Mutants with K65R and M184V linked on the same genome were the most common HIV-1 variants in samples analysed from patients failing TNV, ddI and 3TC with both mutations detected by standard genotype. The double mutant exhibited reduced susceptibility to all three NRTIs in the regimen. This resistant phenotype, resulting from just two linked point mutations, likely contributes to rapid failure of NRTI combinations that exclude zidovudine.
Combinations of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) have been studied as initial therapy of HIV type-1 (HIV-1) infection with goals of regimen simplification and sparing of other drug classes. Unfortunately, such combinations, especially those excluding zidovudine (AZT), have been associated with rapid viral rebound [1] [2] [3] [4] .
One such study [1] tested a combination of oncedaily tenofovir (TNV), didanosine (ddI) and lamivudine (3TC) in treatment-naive participants. No patient had >2.0 log 10 decrease in plasma HIV-1 RNA by week 12 and 91% (20/22) went off therapy before week 24 because of inadequate virological response or viral rebound. Standard population phenotyping of samples at treatment discontinuation showed 3TC resistance in 100% (20/20) , no change in TNV susceptibility and reduced susceptibility to ddI in only 16%. Standard population genotyping identified M184V/I in all participants, but K65R in only 10/20. These findings did not adequately explain rapid and consistent regimen failure. We used single genome sequencing to better characterize viral population at failure and to assess linkage between resistance mutations. We also compared population and clonal phenotypes to investigate the observed preservation of TNV and ddI sensitivity.
Methods

Patient samples
Plasma samples were obtained at the time of treatment discontinuation from a trial of once-daily TNV/ ddI/3TC [1] . Samples were available for 9/10 patients who had both M184V and K65R mutations detected by standard genotype, either with or without wild-type as a mixture. This study was approved by the Institutional 
Standard genotypes and phenotypes
Standard genotypes and phenotypes were obtained by the PhenoSense GT assay (Monogram Biosciences, South San Francisco, CA, USA).
Single genome sequences
Single genome sequencing was performed as previously published [5] . Amplicons from complementary DNA dilution having 30% positive PCR reactions were sequenced using ABI Prism BigDye  Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Genomes were assembled using Sequencher version 2.5 (Gene Codes Corp., Ann Arbor, MI, USA) and analysed for resistance mutations using the Stanford Drug Resistance Database algorithm. Sequences showing more than one genome were excluded from analysis (51 in total).
Generation of recombinant clones
Recombinant viruses were generated from plasma samples as reported previously [6] . Plasmids from individual bacterial clones were purified using the Wizard  Plus Minipreps DNA Purification System (Promega, Madison, WI, USA) and sequenced using ABI Prism BigDye  Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems). Clones were transfected into MT-2 cells by electroporation to produce infectious recombinant virus [7] .
Clonal phenotype analyses
Single replication cycle drug susceptibility assays were performed on cloned recombinant viruses as reported previously [8] . Susceptibility assays were performed at least 3× for each virus. Differences in mean 50% inhibitory concentration (IC 50 ) values were assessed for statistical significance using the Mann-Whitney U test.
Results
Standard population genotypes Table 1 shows population genotypes from the time of treatment discontinuation for the nine patients studied. Each sample had both K65R and M184V; six samples had 65R present as a mixture with wild-type K65, and three of these six contained a mixture of 184V with wild-type M184. The only other NRTI resistance mutation detected was 70E, which was found in three samples, each as a mixture with wild-type K70.
Single genome sequences
Multiple (12-46) single genome sequences were obtained from each of nine plasma samples (Table 1) . Of the 204 sequences, 179 (88%) contained M184V and 22 (11%) contained M184I. K65R was detected in 105 (51%) sequences. The most common sequence was the K65R/M184V double mutant in 102/204 (50%), followed by M184V single mutant in 77/204 (38%) and M184I single mutant in 21/204 (10%). The K65R/ M184V double mutant was detected in 8/9 patients. The K65R single mutant was detected in only 2/204 (1%) sequences. K65R/M184I double mutant and wild-type were detected only once each.
Other NRTI mutations were found at low frequency. In total, 5 of 13 sequences had K70E from patient number 5. Other NRTI mutations were detected in only 1-2 sequences (DB et al., data not shown). Standard population phenotypes 
Discussion
This is the first study to perform clonal genotype and phenotype analyses of plasma from patients failing triple NRTI therapy. K65R and M184V were linked on the same genome in 8/9 patients with both mutants detected by standard genotype, and double mutants comprised 50% of all sequences. M184V/I single mutants comprised 48% of all sequences, whereas only two sequences (1%) were K65R single mutants. Frequent linkage of K65R and M184V suggests an advantage for double mutants. Phenotypic analysis of 12 recombinant clones showed a significant decrease in ddI, TNV and ABC susceptibility for K65R/M184V double mutants compared with M184V single mutants (P<0.001). The observed reversal of TNV hypersusceptibility and increased ddI and ABC resistance with the addition of K65R to M184V is consistent with site-directed mutant studies [9, 10] ; however, patient-derived double mutants showed greater resistance to TNV compared with that reported for site-directed mutants [10] , possibly because of different polymorphisms in patient-derived recombinants. Population phenotype analyses failed to accurately measure combined phenotypic effects of . This is probably because population phenotypes represent an average of the variants present. Indeed, the population phenotype of samples with 'pure' K65R and M184V by standard genotype was more similar to that of individual double mutant clones compared with the phenotype of samples with mutant/wild-type 'mixtures', which were more like single M184V clones. Not all of the single genome sequences contained K65R. Furthermore, 10/20 patients had only M184V detected by standard genotype, indicating that double mutants were infrequent or not present in patients with M184I/V alone. Escape of M184I/V single mutants remains unexplained because these viruses were fully susceptible or hypersusceptible to TNV. It might be that TNV does not penetrate or is not phosphorylated to its active metabolite in certain target cells, allowing the M184V single mutant to replicate. This possibility is supported by observations that TNV alone is not fully suppressive of HIV-1 replication [11, 12] and its tissue penetration is variable [13] .
A negative drug-drug interaction between TNV and other NRTIs has also been proposed as an escape mechanism of M184V/I single mutants from TNV suppression; however, Hawkins et al. [14] and Lanier et al. [15] did not detect pharmacological antagonism between 3TC, ABC and TNV. Similarly, Kearney et al. [16] did not detect an effect of ddI on TNV concentrations. Although these studies failed to identify major negative drug-drug interactions, metabolism at the single cell level was not studied and thus antagonism cannot be entirely excluded.
Delaunay et al. [17] clonally analysed longitudinal samples from five patients in the TONUS study of TNV/3TC/ABC. Linkage analysis showed K65R and M184V/I single mutants were more prevalent at week 4 than at week 12. By week 12, double mutants containing K65R and M184V/I were predominant in all five patients. These data are consistent with our finding of frequent double mutants at treatment discontinuation (week 16 or later).
Failure of triple-NRTI regimens [1] [2] [3] [4] does not occur as frequently in regimens containing AZT [18] [19] [20] . For example, ACTG A5095 [18] compared the efficacy AZT/3TC/ABC, AZT/3TC/efavirenz and AZT/3TC/ABC/efavirenz. Although the triple-NRTI regimen was inferior to efavirenz-containing arms, it did suppress HIV-1 RNA to <50 copies/ml in 61% of patients at week 48. Similarly, TARGET [19] , a single-arm trial of twice-daily 3TC/AZT/ABC, showed HIV-1 RNA suppression to <50 copies/ml in 56% of patients. Finally, NZTA4007 [20] , a single-arm trial of 3TC/AZT/ABC, achieved HIV-1 RNA suppression to <50 copies/ml in 75% of patients at 24 weeks. The substantially better virological response of AZTcontaining triple NRTI regimens might be caused by phenotypic antagonism between the common resistance pathways for AZT (thymidine analogue mutations) versus TNV, 3TC, ABC and ddI (K65R and M184V) [10] . This possibility is supported by the a Clones are designated by the sample number from which they were derived followed by a letter designating the specific clone sequence. Table 3 . Clonal genotypes and phenotypes absence of K65R at virological failure in A5095 and TARGET compared with its high prevalence in studies of NRTI regimens excluding AZT. In summary, the poor virological response and rapid viral rebound observed with once-daily TNV/ddI/3TC is explained in some patients by resistance to each component of the regimen resulting from two linked single nucleotide mutations in reverse transcriptase (K65R and M184V).
